MOUNTAIN VIEW, Calif., June 19, 2012 (GLOBE NEWSWIRE) -- Complete Genomics, Inc. (Nasdaq:GNOM), announced today that it intends to vigorously defend itself against the patent infringement suit recently filed by Illumina, Inc. in the U.S. District Court for the Southern District of California. The complaint alleges that Complete infringes a single Illumina patent relating to a "Method for Sequencing a Polynucleotide Template." Complete considers the lawsuit to be wholly without merit.
"Despite this move by Illumina, we remain fully committed to the strategy and actions that we recently announced," stated Dr. Clifford A. Reid, Ph.D., Complete's chairman, president and chief executive officer. "We will continue to fully service and support our customers while defending against this lawsuit. This is yet another attempt by Illumina to compete in the courtroom instead of the marketplace and reflects the extent to which it sees Complete's more accurate genome sequencing technology as a competitive threat."
In August 2010, Illumina sued Complete for infringement of another patent, in a case now pending in the U.S. District Court for the Northern District of California. Complete considers that suit to also be without merit and recently filed a motion for summary judgment setting forth numerous grounds for the patent in issue being declared invalid.
About Complete Genomics
Complete Genomics is the whole human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA™ Platform) combines proprietary human genome sequencing technology with advanced informatics and data management software. Additional information can be found at www.completegenomics.com.
Caution Regarding Forward-Looking Statements
This Press Release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended, including statements regarding the Complete Genomics, Inc. intention to defend itself against the lawsuits brought against it by Illumina, Inc. These forward-looking statements are based on management's current expectations, are not guarantees of future performance, and involve certain risks and uncertainties that could cause actual results to differ materially from management's current expectations and these forward-looking statements. These risks and uncertainties include, but are not limited to, the complexities, expense and unpredictability of litigation, and other risks detailed in the company's most recent Annual Report on Form 10-K, filed with the SEC on March 9, 2012, and Quarterly Report on Form 10-Q, filed with the SEC on May 9, 2012. The company disclaims any obligation to update information contained in its forward-looking statements, whether as a result of new information, future events or otherwise.